U.S. Medical
This site is intended for U.S. Healthcare Professionals.
To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
This site is intended for U.S. Healthcare Professionals.
To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
Not an actual patient.
Inflammatory Bowel Disease
Approximately 1.6 million Americans have IBD,1,2 which is comprised of 2 major types: ulcerative colitis (UC), characterized by continuous, mucosal inflammation limited to the innermost lining of the colon and rectum, and Crohn’s disease (CD), defined by patchy, transmural inflammation which can affect any part of the gastrointestinal (GI) tract, from the mouth to the perianal area.1,3,4
Epidemiology
Population-based studies in the U.S. suggest that the incidence of IBD is most common in patients aged 15 to 35 years.1 IBD can also present in childhood, including up to 20% of children who are diagnosed before the age of 10 years.5 It is more common in Whites (vs other racial groups) and in adults, UC is more common in males.1,6
Diagnosis
Symptoms of IBD depend on the disease location, and can range from mild to moderate to severe.2,4 Diarrhea and rectal bleeding are characteristic with UC. Patients can experience weight loss and fever (although it can be less common than with CD), and abdominal pain varies depending on the patient. For CD, weight loss, fever, and abdominal pain are more predominant, although these patients can also experience diarrhea and rectal bleeding.4
Irritable bowel syndrome (IBS), the most common GI condition diagnosed by gastroenterologists, may be mistaken for IBD since IBS symptoms may mimic those seen in a patient with mild IBD, but history and additional diagnostic tests can help rule it out of the differential diagnosis.7 Endoscopy combined with biopsies of the affected area(s) of the GI tract will also establish the diagnosis and differentiate between UC and CD.4,8
Pathophysiology
The etiology of IBD most likely involves a complex interaction between genetic and environmental factors, microbiome, and the immune system.3,4 T cells, which are activated by antigen-presenting cells in the peripheral lymphoid tissue, migrate to the site of inflammation and play a role in recruitment and activation of additional inflammatory cells in the GI tract.9,10
Navigating IBD
IBD is a chronic disease, with significant impact on a patient’s general health.3 While the Crohn’s Disease Activity Index (for CD) and Mayo Score (for UC) are the most frequently used instruments for scoring and monitoring disease activity in clinical trials, researchers are working to improve the measures of disease activity and severity through assessment of impact of disease on the patient, disease burden, and disease course, including structural damage with a goal of improving disease management for patients.11
- Shivashankar R, Tremaine WJ, Harmsen WS, et al. Clin Gastroenterol Hepatol. 2017;15(6): 857-863.
- Crohn’s and Colitis Foundation of America. Factbook. 2014. Available at:
https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf. Last accessed September 2, 2021. - Latella G and Papi C. World J Gastroenterol. 2012;18(29):3790-3799.
- Podolsky DK. N Engl J Med. 2002;347(6):417-429.
- Abramson O, Durant M, Mow W, et al. J Pediatr. 2010;157(2):233-239.
- Dahlhamer JM, Zammitti EP, Ward BW, et al. MMWR. 2016;65(42):1166-1169.
- Burgmann T, Clara I, Graff L, et al. Clin Gastroenterol Hepatol. 2006;4(5):614-620.
- Andresen V, Whorwell P, Fortea J, et al. United Eur Gastroenterol J. 2015;3(1):39-52.
- Ley K and Kansas GS. Nat Rev Immunol. 2004;4:1-11.
- Sheridan BS and Lefrançois L. Nat Immunol. 2011;12(6):485-491.
- Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2016;14(3):348-354.
Clinical Trials
Find information about Takeda-sponsored clinical trials. See how our patient-driven philosophy fuels our scientific discovery as we strive to address important medical and scientific questions.
Scientific Congresses in Gastroenterology
Plan to attend upcoming congresses in gastroenterology, or explore resources, data, and presentations from past events to stay informed.
Medical Inquiries
U.S. Medical Affairs at Takeda is here to provide you with access to scientific information. Let us know how we can help.
TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited. MEDCONNECT™ is a trademark of Takeda Pharmaceuticals U.S.A., Inc.
©2023 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.
Welcome to U.S. Medical Affairs at Takeda
This site is intended only for healthcare professionals registered to practice in the U.S. and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. The information is not intended as medical advice and may be incomplete. This resource may include information that has not been approved by the U.S. Food and Drug Administration (FDA). Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional.
Choose an option that describes you:
By clicking on this option, I certify that I am a U.S. healthcare professional.
Select a product and enter keywords to search for specific product information
Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.